Varying data on the effect of thiamine therapy on SLC19A2-diabetes were available for 95 patients (at the individual level, n = 72 patients; at group level n = 23 in one case series) (Table 8, Supplemental Table 10, and Supplementary Data 1). The gene discussed is SLC19A2; the disease is diabetes mellitus.